Spectrum of F8 Genotype and Genetic Impact on Inhibitor Development in Patients with Hemophilia A from Multicenter Cohort Studies (J-HIS) in Japan

Abstract Some genetic and treatment-related factors are risk factors for inhibitor development in patients with hemophilia A (PwHA). However, the genotype distribution of the factor VIII gene (F8) and genetic impact on inhibitor development in Japanese PwHA remain unknown. In 2007, the Japan Hemophilia Inhibitor Study 2 (J-HIS2) was organized to establish a nationwide registry system for hemophiliacs and to elucidate risk factors for inhibitor development, designed for prospective investigation following a retrospective study (J-HIS1) which had already finished. Patients, newly diagnosed after January 2007, were enrolled in J-HIS2 and followed up for inhibitor development and clinical environments since 2008 onward. In the present study, F8 genotypes of PwHA were investigated in the patients recruited from the J-HIS2 cohort as well as those with inhibitor from the J-HIS1 cohort. F8 variants identified in 59 PwHA with inhibitor in J-HIS1 were: 20 intron-22 inversions, 5 intron-1 inversions, 9 large deletions, 4 nonsense, 8 missense, 11 small in/del, and 2 splice-site variants. F8 variants identified in 267 (67 with inhibitor) PwHA in J-HIS2 were: 76(28) intron–22 inversions, 3(2) intron–1 inversion, 1(0) duplication, 8(5) large deletions, 21(7) nonsense, 109(7) missense, 40(11) small in/del, and 9(7) splice-site variants. Forty variants were novel. The cumulative inhibitor incidence rate in the severe group with null changes was 42.4% (95% confidence interval [CI]: 33.7–50.8), higher than that with nonnull changes (15.6% [95%CI: 6.8–27.8]), in J-HIS2. Relative risk for inhibitor development of null changes was 2.89. The spectrum of F8 genotype and genetic impact on inhibitor development in Japanese PwHA were consistent with the previous reports.

[1]  D. Hampshire,et al.  The European Association for Haemophilia and Allied Disorders (EAHAD) Coagulation Factor Variant Databases: Important resources for haemostasis clinicians and researchers , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

[2]  K. Nogami,et al.  Contribution of Factor VIII A2 Domain Residues 400–409 to a Factor X-Interactive Site in the Factor Xase Complex , 2018, Thrombosis and Haemostasis.

[3]  F. Rosendaal,et al.  Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement , 2018, Journal of thrombosis and haemostasis : JTH.

[4]  X. Wu,et al.  Spectrum and origin of mutations in sporadic cases of haemophilia A in China , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

[5]  J. Shendure,et al.  Novel approach to genetic analysis and results in 3000 hemophilia patients enrolled in the My Life, Our Future initiative. , 2017, Blood advances.

[6]  Raymond Dalgleish,et al.  HGVS Recommendations for the Description of Sequence Variants: 2016 Update , 2016, Human mutation.

[7]  K. Nogami,et al.  Mild hemophilia A patient with novel Pro1809Leu mutation develops an anti‐C2 antibody inhibiting allogeneic but not autologous factor VIII activity , 2015, Journal of thrombosis and haemostasis : JTH.

[8]  D. Middleton,et al.  Determination of HLA‐A, ‐C, ‐B, ‐DRB1 allele and haplotype frequency in Japanese population based on family study , 2015, Tissue antigens.

[9]  D. Moss,et al.  A large‐scale computational study of inhibitor risk in non‐severe haemophilia A , 2015, British journal of haematology.

[10]  K. Nogami,et al.  The first case of int1h‐related inversion in Japanese haemophilia A patients , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  K. Nogami,et al.  Long-term treatment course of a patient with mild haemophilia A who developed a high titre factor VIII inhibitor , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[12]  J. Astermark,et al.  GENERAL INTRODUCTION AND OUTLINE OF THE THESIS , 2012 .

[13]  J. Oldenburg,et al.  Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. , 2013, Blood.

[14]  C. Miller,et al.  The CDC Hemophilia A Mutation Project (CHAMP) Mutation List: A New Online Resource , 2013, Human mutation.

[15]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[16]  S. Kim,et al.  Mutation spectrum and inhibitor risk in 100 Korean patients with severe haemophilia A , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[17]  C. Hermans,et al.  Computational and molecular approaches for predicting unreported causal missense mutations in Belgian patients with haemophilia A , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[18]  M. Margaglione,et al.  F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. , 2012, Blood.

[19]  P. Fay,et al.  Factor VIII light chain contains a binding site for factor X that contributes to the catalytic efficiency of factor Xase. , 2012, Biochemistry.

[20]  J. Takamatsu,et al.  An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[21]  J. G. van der Bom,et al.  Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[22]  Y. Sakata,et al.  The Factor VIIIa C2 Domain (Residues 2228–2240) Interacts with the Factor IXa Gla Domain in the Factor Xase Complex* , 2009, Journal of Biological Chemistry.

[23]  Chien-Nan Lee,et al.  Mutation spectrum of 122 hemophilia A families from Taiwanese population by LD-PCR, DHPLC, multiplex PCR and evaluating the clinical application of HRM , 2008, BMC Medical Genetics.

[24]  B. Shen,et al.  The tertiary structure and domain organization of coagulation factor VIII. , 2008, Blood.

[25]  M. Asgharzadeh,et al.  Identification of a novel missense mutation in exon 4 of the human factor VIII gene associated with sever hemophilia A patient. , 2007, Pakistan journal of biological sciences : PJBS.

[26]  J. Astermark,et al.  Polymorphisms in the CTLA‐4 gene and inhibitor development in patients with severe hemophilia A , 2007, Journal of thrombosis and haemostasis : JTH.

[27]  T. Lambert,et al.  Detection of 95 novel mutations in coagulation factor VIII gene F8 responsible for hemophilia A: results from a single institution , 2006, Human mutation.

[28]  J. Astermark,et al.  Polymorphisms in the IL-10 but not in the IL-1{beta} and IL-4 genes are associated with inhibitor development in patients with hemophilia A. , 2006 .

[29]  B. Dworniczak,et al.  Spectrum of molecular defects and mutation detection rate in patients with severe hemophilia A , 2005, Human mutation.

[30]  K. Nogami,et al.  Mechanisms of Interactions of Factor X and Factor Xa with the Acidic Region in the Factor VIII A1 Domain* , 2004, Journal of Biological Chemistry.

[31]  M. Shima,et al.  Inversions of the Factor VIII Gene in Japanese Patients with Severe Hemophilia A , 2004, International journal of hematology.

[32]  P. Fay.  Activation of factor VIII and mechanisms of cofactor action. , 2004, Blood reviews.

[33]  C. Rosano,et al.  Analysis of 18 novel mutations in the factor VIII gene , 2003, British journal of haematology.

[34]  A. Ganguly,et al.  High throughput mutation screening of the factor VIII gene (F8C) in hemophilia A: 37 novel mutations and genotype–phenotype correlation , 2002, Human mutation.

[35]  A. Thompson,et al.  Non-Inversion Factor VIII Mutations in 80 Hemophilia A Families Including 24 with Alloimmune Responses , 2002, Thrombosis and Haemostasis.

[36]  A. Thompson,et al.  Some factor VIII exon 14 frameshift mutations cause moderately severe haemophilia A , 2001, British journal of haematology.

[37]  F. Rosendaal,et al.  Definitions in Hemophilia , 2001, Thrombosis and Haemostasis.

[38]  P. Lenting,et al.  Electron Crystallography of Human Blood Coagulation Factor VIII Bound to Phospholipid Monolayers* , 1999, The Journal of Biological Chemistry.

[39]  K. Fujikawa,et al.  Structure of the C2 domain of human factor VIII at 1.5 Å resolution , 1999, Nature.

[40]  C. Kessler,et al.  The genetic basis of inhibitor development in haemophilia A , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[41]  S. Antonarakis,et al.  Partial correction of a severe molecular defect in hemophilia A, because of errors during expression of the factor VIII gene. , 1997, American journal of human genetics.

[42]  K. Fukutake,et al.  Inversion in Japanese Patients with Hemophilia A , 1995, Thrombosis and Haemostasis.

[43]  Stylianos E. Antonarakis,et al.  Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A , 1993, Nature Genetics.

[44]  Masoud Parsania,et al.  THE PATIENTS , 1982, California state journal of medicine.

[45]  Jay Martin.  On Japan , 1978, Current History.

[46]  P. Byers.  Killing the messenger: new insights into nonsense-mediated mRNA decay. , 2002, The Journal of clinical investigation.

[47]  P. Green,et al.  Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe hemophilia A. , 2002, Blood.

[48]  G. Tagariello,et al.  Experience of a single Italian center in genetic counseling for hemophilia: from linkage analysis to molecular diagnosis. , 2000, Haematologica.